Tunable differentiation of human CD4+ and CD8+ T cells from pluripotent stem cells

Ross D. Jones,Kevin Salim,Laura N. Stankiewicz,John M. Edgar,Lorna Leon,Jana K. Gillies,Ali Murtaza,Lauren J. Durland,Divy Raval,Thristan P. Taberna,Han Hsuan Hsu,Carla Zimmerman,Yale S. Michales,Fabio M. V. Rossi,Megan K. Levings,Peter W. Zandstra

DOI: https://doi.org/10.1101/2024.10.29.620998

2024-11-03

Abstract:Allogeneic T cell therapies are a highly desirable option to circumvent the cost and complexity of using autologous T cells to treat diseases. Allogeneic CD8+ T cells can be made from pluripotent stem cells (PSCs), but deriving CD4+ T cells from PSCs remained a significant challenge. Using feeder- and serum-free conditions, we found that CD4+ versus CD8+ T cell commitment from PSCs can be controlled by fine-tuning the dynamics of Notch and T cell receptor signaling delivered to CD4+CD8+ double positive T cells. Notch signaling negatively impacts CD4+ T cell commitment, and its timed removal allows generation of clonally-diverse and expandable CD4+ T cells from PSCs. The resulting CD4+ T cells respond to cytokine-mediated polarization by differentiating into Th1, Th2, or Th17 cells, recapitulating canonical helper cell function. These findings represent a significant step towards using PSC-derived CD4+ T cells as a low cost, off-the-shelf, cell therapy.

Bioengineering

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is: **How to efficiently and controllably generate CD4+ T cells from pluripotent stem cells (PSCs)** in order to achieve low - cost and large - scale production of allogeneic T - cell therapies.

### Problem Background:
1. **Importance of T - cell therapies**: Engineered T - cells have great potential in treating cancer, autoimmune diseases, and infectious diseases. However, the manufacturing and management of autologous (patient - derived) T - cells are costly and complex, which limits their wide application.
2. **Advantages of allogeneic T - cells**: Allogeneic T - cells (i.e., "off - the - shelf" T - cells) can be produced from pluripotent stem cells (PSCs) and are scalable and cost - effective. Currently, CD8+ T - cells can be differentiated from PSCs under feeder - free and serum - free conditions, but generating a large number of mature CD4+ T - cells remains a major challenge.
3. **Importance of CD4+ T - cells**: CD4+ T - cells are key coordinators in the immune system. They can help CD8+ T - cells function better and regulate various immune responses by differentiating into different helper T - cell subsets (such as Th1, Th2, and Th17). Therefore, the lack of CD4+ T - cells may limit the clinical efficacy of PSC - derived T - cell therapies.

### Research Objectives:
This research aims to control the differentiation of PSCs into CD4+ T - cells by optimizing the kinetics of Notch signaling and TCR signaling, thereby achieving the following goals:
- **Increasing the yield of CD4+ T - cells**: Promote the generation of CD4+ T - cells by regulating the intensity and time of Notch signaling and TCR signaling.
- **Ensuring the functionality of CD4+ T - cells**: The generated CD4+ T - cells should be able to respond to the polarizing effects of cytokines and differentiate into different types of helper T - cells.
- **Achieving the generation of CD4+ and CD8+ T - cells with a controllable ratio**: By adjusting the levels of Notch and TCR signaling, the ratio of CD4+ and CD8+ T - cells can be controlled in the same culture system.

### Main Findings:
1. **Effect of Notch signaling on the generation of CD4+ T - cells**: Notch signaling inhibits the generation of CD4+ T - cells, and timely removal of Notch signaling can generate CD4+ T - cells with high clonal diversity and scalability.
2. **Effect of TCR signaling intensity**: High - level TCR stimulation tends to generate more CD8+ T - cells, while low - level TCR stimulation is helpful for generating CD4+ T - cells.
3. **Functional verification**: The generated CD4+ T - cells can respond to the polarizing effects of cytokines and differentiate into Th1, Th2, or Th17 cells, showing typical helper cell functions.

These findings lay an important foundation for using PSC - derived CD4+ T - cells as a low - cost, off - the - shelf cell therapy.